Eiko Lifesciences
- Market cap
- ₹ 73 Cr.
- P/E
- 14.6x
- P/B
- 1.02x
- 52-week range
- 43 – 64.44
- ROE
- 7%
- ROCE
- 11.1%
- Dividend yield
- 0%
- Debt / equity
- 0.07
- Sector
- Chemicals & Petrochemicals
- Industry
- Specialty Chemicals
- Listed on
- BSE
About
Eiko LifeSciences Limited is an India-based company engaged in manufacturing, processing, formulating, producing, buying, selling, and exporting specialty and fine chemicals. It operates in the Specialty & Fine Chemicals segment. It offers products in Specialty Chemicals and Intermediates, Application Programming Interfaces (APIs), Agrochemical Intermediates, Flavor & Fragrances, and Cosmetic Emollients. Specialty Chemicals and Intermediates include Lasamide, Trichloro Salicylic acid, Chloroacetyl Xylidide and Thiodipropionic acid. Agrochemical Intermediates include 5-chloro-8-hydroxyquinoline. Cosmetic Emollients include Isopropyl Oleate, Isopropyl Laurate, Isopropyl Palmitate, Isopropyl Myristate, Methyl Myristate, Butyl Oleate, Butyl Laurate, and Methyl Myristate, among others. APIs include Topiramate Indian Pharmacopoeia (IP), (United States Pharmacopeia) USP/ European Pharmacopeia (EP), and Glucosamine hydrochloride (HCL)/Sodium/Potassium USP/EP, among others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Specialty Chemicals: 130 companies →Eiko Lifesciences against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)14.6 against a typical 25.8: cheaper than most peers (1st = cheapest).34th of 129
- Sales growth+56.4% against a typical +25.9% from a year earlier.19th of 112
- Profit growth+36% against a typical +42.4% from a year earlier.56th of 102
- Share price, 3 months+1.4% against a typical −5.8%.46th of 118
- Size₹ 72.5 Cr. market value against a typical ₹ 359.6 Cr. (1st = largest).98th of 126
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Mar 2020 | Jun 2020 | Sep 2020 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 1 | 1 | 11 | 8 | 7 | 11 | 11 | 12 | 12 | 18 | 17 |
| Expenses | 2 | 0 | 1 | 10 | 8 | 7 | 10 | 9 | 10 | 10 | 16 | 15 |
| Operating Profit | −1 | 0 | −0 | 0 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| OPM % | −146.8% | 25% | −6% | 3.7% | 5.3% | 8.4% | 11.7% | 14.1% | 15.2% | 15.7% | 12.3% | 11.5% |
| Other Income | −0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −1 | 0 | −0 | 0 | 0 | 1 | 2 | 1 | 2 | 2 | 2 | 2 |
| Tax % | −28.2% | 28.6% | −22.2% | 26.1% | 27.8% | 25% | 23.8% | 25% | 24.6% | 24.7% | 25.7% | 24.5% |
| Net Profit | −1 | 0 | −0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 |
| EPS in Rs | −0.64 | 0.09 | −0.08 | 0.3 | 0.22 | 0.33 | 0.84 | 0.66 | 0.79 | 0.88 | 0.91 | 0.91 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 56%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 102%
- 10 Years
- —
- 5 Years
- −11%
- 3 Years
- −7%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Eiko Lifesciences | ₹ 50.00 | ₹ 73 Cr. | 14.6x | 1x | 7% | — |
| Asian Paints | ₹ 2,305.00 | ₹ 2,21,095 Cr. | 56.7x | 11.8x | — | 13% |
| Solar Industries India | ₹ 18,320.00 | ₹ 1,65,778 Cr. | 103.2x | 29x | — | 18.1% |
| Pidilite Industries | ₹ 1,514.00 | ₹ 1,54,107 Cr. | 68.2x | 15.5x | — | 17.4% |
| SRF | ₹ 2,309.00 | ₹ 68,444 Cr. | 40.1x | 5.5x | — | 12.7% |
| Berger Paints India | ₹ 465.60 | ₹ 54,289 Cr. | 50.8x | 8.5x | — | 9.9% |
Management
- Jaid Ismail Kojar
- Chief Financial Officer
- Chintan Bharatbhai Doshi
- Compliance Officer, Company Secretary
- Sumukh Prabhakar Vartak
- Additional Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.